After being fired, I became the light of medicine

Chapter 185 Siemens’ countermeasures!

Chengdu Third People's Hospital, Director's Office.

Dean Zhou's full name is Zhou Yongren. As early as when Qingshan Pharmaceutical just developed "ITG human myelopoietin", Dean Zhou established a good personal relationship with Zhang Yang and became a strategic partnership with Qingshan Pharmaceutical.

In recent years, Qingshan Pharmaceutical has lived up to expectations. With many innovative drugs such as "ITG Human Myelopoietin", "Ikefenprovir", "Hepatocyte Activator", and "Renal Dialysis Needle", it has conducted exclusive clinical trials in the Third People's Hospital, which has also brought countless patients to the hospital for treatment.

The medical staff of key departments such as Hematology, Hepatology, and Nephrology have been significantly improved, and the department rankings have also moved forward significantly!
You know, the annual rankings of major departments determine the hospital's annual comprehensive score, and the comprehensive score is largely an assessment of the hospital director, and to a large extent reflects how well the hospital director is doing.

Looking at the comprehensive score he estimated, Dean Zhou frowned worriedly.

There will be a new round of personnel adjustments in less than half a year. He certainly doesn't want to continue staying in the position of dean. He certainly wants to go further.

According to the original plan, or goal, his next position was to be the deputy director of the Chengdu Municipal Health Commission.

This is an important functional department that can coordinate and plan the medical policies, medical supervision and other work of the entire Chengdu city. It can be said that once transferred from the hospital to the deputy director, it means rising from the micro-management of the hospital to the macro-management of the entire regional medical care.

It’s exciting just thinking about it.

but……

Although I have achieved very good results with the help of Qingshan Pharmaceutical in the past few years, the overall profitability of the hospital, medical resources, and highly educated doctors have also improved dramatically,

But he also knew that the other dean who was competing with him for the deputy director position had also done a good job over the years!

It would be a lie to say you are not worried.

“It would be great if we could create another star department in the next six months and get into the top 50 in the country!”

"This way, my position as deputy director will definitely be secure!"

Dean Zhou sighed in his heart and couldn't help rubbing his temples.

It sounds simple, but at present, the only one that can really produce some results quickly is the "nano-nodule contrast agent" of Tsingshan Pharmaceutical, which is currently undergoing phase II clinical trials.

But the problem is that the number of patients recruited in the second and third phases of clinical trials is fixed. Although these patient data can improve some rankings, it is still very difficult to enter the top 50 departments in the country at one time!
Moreover, the ranking of departments also depends on the average number of surgeries per day. Once the "nano-nodule contrast agent" is fully available on the market, a large number of patients will inevitably be diverted. Where will the departments get the constant supply of patients?
Oh, if only I could have it all to myself for a month!
A CT scan can examine 200 patients a day, which translates to 6000 patients a month.

It won’t take a month, it will be basically stable in half a month!
But where does the half-month exclusivity come from?

Dean Zhou shook his head. At this moment, the office door was suddenly pushed open and the newly appointed director of thoracic surgery, Ouyang, walked in with a stack of information.

"Dean Zhou, I have finished organizing the information you asked me to organize. Please take a look."

Dean Zhou looked up at the newly promoted Director Ouyang, and a hint of kindness appeared on his originally frowning face.

I have to mention here that Director Liu of the Department of Thoracic Surgery of the Third People's Hospital has been dismissed by Director Zhou. Just because he was able to judge Feng Gang's benign nodule as malignant, and after Feng Gang had surgery in vain, Director Zhou no longer trusted him.

It happened that Qingshan Pharmaceutical's "Nano-nodule Contrast Agent" was undergoing an exclusive clinical trial at Sanren Hospital, which attracted inquiries from many young and energetic doctors, so they simply replaced him with the more capable Director Ouyang.

"Thanks a lot."

Dean Zhou took the data compiled by Director Ouyang and began to read it. Director Ouyang, who was standing beside him, said:

"I compiled all the surgical data from the Phase I and Phase II clinical trials of the 'nano-nodule contrast agent' in our hospital."

"There are a total of 263 surgeries performed in our department, of which 221 were minimally invasive surgeries, 31 were open-chest surgeries, and the remaining 11 were relatively difficult..."

"However, with only more than 260 surgeries, it is difficult for our department to improve its ranking significantly."

Dean Zhou frowned, knowing the difficulty.

The most important scoring criteria in department rankings are "case data" and "scientific research capabilities".

There is no need to say much about "scientific research capabilities". The thoracic surgery department of Sanren Hospital has no scientific research capabilities at all, so the most important things are case data and surgical data.

More than 260 surgeries are clearly not enough.

"And Dr. Zhou, I just got some bad news. It is said that because the Phase II clinical data of Qingshan Pharmaceutical's 'nodule contrast agent' is too good, the regulatory authorities are considering significantly reducing the number of subjects in its Phase III clinical trial to speed up its market application."

Reduce the number of subjects in Phase III clinical trials?
Dean Zhou frowned even deeper.

According to the conventional clinical process for innovative drugs, the number of people in Phase I clinical trials is the least, with about a hundred people in Phase II and as many as 500-1000 people in Phase III.

But "nodule contrast agent" is not a traditional medicine, it is just a fluorescent reagent, and can even be classified as "medical consumables"!
With an accuracy rate of up to 100% in the second phase, reducing the number of people in the third phase is in line with regulations.

but……

Dean Zhou was startled, then reacted.

The reduction in the number of Phase III clinical trial subjects is certainly a good thing for Qingshan Pharmaceutical, but it is not a good thing for itself and the Department of Thoracic Surgery of Chengdu Third People's Hospital!
Director Ouyang saw the painful expression on Dean Zhou's face. He knew that Dean Zhou was competing for the position of deputy director, and he also knew that Dean Zhou hoped to improve the ranking of thoracic surgery.

but,

The data of 260 surgeries in Phase I and Phase II clinical trials is obviously insufficient. If there are only 100 surgeries in Phase III clinical trials, it is definitely not enough to improve the ranking.

There's really nothing we can do about it.

Thinking of this, Director Ouyang couldn't help but sigh. After a moment, he suddenly thought of another thing!
"By the way, Dean Zhou, there is one more thing I need to report to you."

"The CT machine manufacturer that cooperates with Qingshan Pharmaceutical, Elephant Medical, has already determined the official price of the 'development CT machine' a few days ago. Each unit is 800 million yuan, which is not too expensive."

"But I heard that their only requirement is that they will not ship and install it until Qingshan Pharmaceutical's 'nodule developer' is on the market."

"Ok?"

"We have to wait until Qingshan Pharmaceutical's 'nodule developer' is on the market before we can ship and install it?"

Dean Zhou was still immersed in the pain of having only 100 subjects in the Phase III clinical trial and did not notice the strangeness in the words.

But at this moment, the phone on the desk suddenly rang. It was Zhang Yang calling.

Before anyone could speak, Zhang Yang spoke first:

"Director Zhou, didn't you order a 'nodule imaging CT machine' from Elephant Medical? When it's convenient for you, I'll arrange for someone to deliver it to your door and install it."

Dean Zhou gradually came to his senses and remembered what Director Ouyang said just a second ago.

He was a little surprised and said in amazement:
"Zhang Yang, I just heard that your 'nodule imaging CT machine' will not be shipped and installed until Qingshan Pharmaceutical's 'nodule contrast agent' is on the market," "Why are you suddenly shipping it to us?"

Zhang Yang laughed and explained:
"Dean Zhou, you are really well-informed."

"It's like this. Our 'nodule contrast agent' is about to enter phase III clinical trials. I estimate that the phase III trial of about 100 subjects will be completed in about a month, and it will be successfully launched in one and a half months at most."

"This is installed in advance, so that you can use the developer as soon as it goes on sale."

Dean Zhou was stunned, then said:
"Then why don't you ship the orders from other hospitals together?"

But as soon as he said this, he suddenly started to understand everything.

After a moment, a warm current suddenly surged in his heart, and his voice became low, surprised, and unbelievable:
"Zhang Yang, do you mean that you asked Elephant Medical to only deliver the goods to us in advance?"

"Are you deliberately leaving us some time? Let the Third People's Hospital have exclusive use of the 'developer' for a while?"

Zhang Yang did not hide it and said with a smile:
"Yes, I told them to wait until the 'developer' is on the market before shipping it."

"This way, you will have about half a month of exclusive time! During this half month, your Third People's Hospital is the only one in the country that can perform 'lung nodule scans'. I believe it will be very helpful to your patients, right?"

"Dean Zhou, you must seize the opportunity!"

"Zhang Yang..."

After getting the confirmation, Dean Zhou's heart was already surging with excitement.

He originally wanted to ask something like "Why are you so nice to me?", but when the words came to his lips, all the words seemed to become pale.

He and Zhang Yang have known each other since "ITG Human Myelopoietin". It seems that Zhang Yang has always been this kind of person over the years!

After being silent for dozens of seconds, he suddenly whispered:
"Thank you, thank you Zhang Yang!"

"Haha, Director Zhou is too polite. Please quickly arrange for someone to receive the CT machine. Our people have arrived. That's it. I'll hang up first!"

Zhang Yang’s call came quickly and went away quickly.

He had no time to sigh, and hurriedly told Director Ouyang to go to the CT room to receive the "nodule imaging CT machine" from Elephant Medical.

Director Ouyang left quickly, and only Dean Zhou was left in the office. His eyes fell on the prominent phone number on the screen of his mobile phone, and he could no longer hold back on venting the excitement in his heart.

"Zhang Yang...I will remember your friendship!"

"You helped me get promoted to deputy director, and I will repay you a hundredfold when the time comes!"

Unconsciously, Dean Zhou made a promise in his heart.

……

The news that Elephant Medical's CT machines "will not be shipped or installed until 'nodule contrast agent' is on the market" quickly spread among the purchasing departments of major hospitals.

Although the major hospitals felt it was a bit strange, they could accept it.

Just as Elephant Medical explained, the "nodule contrast function" of CT can only be officially used after the "nodule contrast agent" is on the market, and it will not be too late to install it then.

Of course, there are hospitals that have expressed doubts.

After all, any manufacturer of medical devices would like customers to place orders quickly and have the equipment delivered to hospitals quickly. Only Elephant Medical is still dragging its feet on delivery. Does it think it is making too much money?
However, although everyone had some complaints, considering that the price far exceeded psychological expectations and that a "nodule imaging CT machine" could be purchased for only 800 million yuan, major hospitals, including Union Hospital, Huaxia Hospital, Ruijin Hospital, Shanghai Cancer Hospital, etc., signed the purchase contract very readily.

A week later, in Shanghai, at Elephant Medical Headquarters.

Mao Zhiqiang looked at the orders that came in like snowflakes, and he couldn't suppress the smile on his face!

In just one week, a total of 14 well-known domestic hospitals signed purchase agreements with Elephant Medical, with the purchase quantity reaching 58 units!
You know, each "nodule imaging CT machine" has a gross profit of 35%, which means one machine can make 280 million, and 58 machines would make 1.6 million!
In the past, this would have been a year’s profit or even more than a year’s profit!

"Great! It feels so good, it's really worth hugging this thigh!"

……

Mao Zhiqiang was delighted by the successful start of Elephant Medical. On the other hand, Siemens headquarters also noticed that Elephant Medical had won a large number of hospital orders and was developing rapidly!
The source of everything is Qingshan Pharmaceutical’s “nodule developer”!
Actually,
As early as when Zhang Yang withdrew his intention to cooperate with Siemens, Siemens headquarters noticed Tsingshan Pharmaceutical's "nodule contrast agent" that was enough to change the CT market landscape. Vice President Peter even flew to China immediately to discuss cooperation with Zhang Yang in person.

but,

When Vice President Peter discussed cooperation with Zhang Yang, Qingshan Pharmaceutical had already started cooperation with Elephant Medical, so Zhang Yang directly refused.

When Vice President Peter expressed his hope that Elephant Medical would not have a monopoly on the patent and was willing to cooperate and pay patent fees, Zhang Yang had already taken the lead in obtaining 50% of the shares of Elephant Medical and ultimately had no choice but to reject Siemens' request for cooperation.

Of course, if it were someone else, they would definitely be willing to cooperate with Siemens. After all, the size of Siemens is completely different from that of Elephant Medical.

But Qingshan Pharmaceutical earns tens of billions in profits a year, so Zhang Yang doesn't really care about Siemens' patent fees.

that's it,
The cooperation between Siemens headquarters and Tsingshan Pharmaceutical ended before it even began.

Siemens headquarters in Germany.

In a spacious and bright conference room with a high-tech feel, Vice President Peter, who had met Zhang Yang once before, sat on the left side of the conference table. He was the host of the meeting today.

There are six other senior executives on both sides of him. Except for President Tobias, the others are vice presidents in charge of various businesses like him.

He glanced at CEO Tobias, saw him nod, then coughed lightly and said:

"Everyone is here, so let me tell you the latest situation first!"

"We all know that Tsingshan Pharmaceutical, a well-known pharmaceutical company in China, has developed a drug called 'Nano-nodule Contrast Agent' and has reached a cooperation with 'Elephant Medical', one of our direct competitors in China."

"A week ago, Elephant Medical officially started selling their 'nodule imaging CT machine' and immediately reached a large number of purchase contracts with major hospitals in China!"

"According to the data we have obtained, their first batch of purchase orders is as high as nearly 60 units, which has reached half of our annual sales in the Chinese market!"

"What surprised me most was that the price of their 'development CT machine' was only 800 million!"

“I’ve already seen the huge impact they’ve had on our product line!”

(End of this chapter)